AZZ: A Record Quarter That Still Hasn't Delivered Its Margin Payoff

AZZ (NYSE:AZZ) just put up the kind of quarter management brags about: record sales in both of its coating businesses, a bigger dividend, and a raised forecast for the full year. The stock is up roughly 28% this year on top of it. None of that is in dispute. The question worth asking before paying ~20 times forward earnings is whether the company's own numbers actually support the story yet — and on that, the quarter is more mixed than the headline.

What AZZ does, and where the growth actually came from

AZZ is North America's largest independent provider of hot-dip galvanizing and coil coatingAZZ is North America's leading independent provider of hot-dip galvanizing and coil coating — the businesses that put a corrosion-resistant layer on steel for bridges, power transmission structures, industrial plants, and building products. It runs two segments: Metal Coatings, which dips finished steel in molten zinc, and Precoat Metals, which roll-coats metal coil before it is formed into products.

In the quarter ended May 31, 2026, Metal Coatings was the clear engine. Sales rose 12.3% to $210.3 millionMetal Coatings Sales of $210.3 million increased by 12.3% on higher volumes across construction, industrial, and infrastructure end markets. That is the part of the business with the most tailwind behind it — galvanizing for electric-grid and data-center work, which does not need a booming office market to keep moving.

Precoat Metals, by contrast, grew only 1.5% to $238.2 millionPrecoat Metals: $238.2 million (up 1.5%), and even that was a marginal lift: the company credited the ramp-up of a new plant in Washington, Missouri and price increases, while volume was actually lower volume in construction and infrastructure. So the quarter that carries the entire year's optimism is really one good segment plus a plant ramp in the other.

The number the headline hides

Here is the tension. Total sales rose 6.3% to a record $448.5 millionTotal Sales: $448.5 million, an increase of 6.3%, and adjusted earnings per share rose 3.9% to $1.85Adjusted Diluted EPS: $1.85. But adjusted EBITDA margin fell from 25.2% to 22.2% — a roughly three-point drop even as revenue hit a high.

That gap is where nearly the whole bull-bear debate sits. The margin compression is largely the new Washington, Missouri facility. Ramping a greenfield coil-coating line is costly: startup inefficiency, extra labor, underutilized capacity, and lower margin on early production before the line runs full and prices stick. Management describes the plant as "accretive to earnings" going forward and, notably, pre-announced that the full-year forecast would be raised to account for it.

So the story the market is paying for is not what happened this quarter — it is what management expects to happen next: the same Washington plant that depressed today's margin converts into a margin contributor, with full-year adjusted EBITDA guidance raised to $375–$415 million and adjusted EPS to $6.75–$7.15.Adjusted EBITDA Guidance: Increased to $375–$415 million That guidance carries the weight of the thesis, and it is a belief about the future, not a reported result.

Business quality versus price

The balance sheet is not the problem. Net leverage is a comfortable 1.4xNet Leverage Ratio: 1.4x, the company plans to cut another $130–$170 million of debt this yearDebt Reduction: Range of $130 – $170 million, and it just hiked the dividend 20% to $0.24 a quarter after 16 consecutive years of paying a dividend. Free cash flow, however, tells a less uniformly happy story: it fell about 56% year over year on the trailing-twelve-month basis, dragged down by a heavier capital-expenditure load as the Washington facility and related capacity soak up cash. TTM free cash flow ran about $169 million against roughly $79 million of capex.

This is the classic pattern to watch in a capital-intensive industrial: revenue can grow on volume while margins and cash conversion lag until the new capacity reaches steady state. That is normal and it can be an excellent setup — but it means the current multiple needs the future margin to be real.

The valuation is the crux. At about $137 a share, AZZ trades near 20 times this year's consensus earnings and roughly 20.8 times trailing earnings, with an EV/EBITDA multiple around 17 times. That is not a cheap cyclical at a trough. The stock has already run from a 52-week low near $93 to a high above $162, and the 20% dividend hike and guidance raise are baked into a price that has rallied 28% year to date. In other words, the easy part of the opportunity — buying fear after it reset — already happened months ago.

The falsifiable window

What makes a growth story investable is evidence, and here the clock is short. The margin recovery the forecast implies should start showing up in the next two reported quarters, beginning with the current fiscal second quarter around October. If the Washington plant genuinely flips from startup drag to contributor, AZZ earns its ~20 times multiple and the raised guidance becomes self-confirming — a decent outcome for holders, and worth a second look on any pullback.

If, instead, volume stays lumpy in Precoat and the plant's margins normalize more slowly than the forecast assumes, then a 20-times multiple on a cyclical with a newly built, unproven line is exposed. The right read right now is not that AZZ is a bad company. It is a good company whose stock has been bid up on a promise that its own most recent quarter only half delivered. For a retail investor without a position, that is a reason to hold off and demand the reported margin proof, not to chase the narrative at full price.